By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report.
To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another.
PMPY = Per Member, Per Year. Source: Artemetrx
By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence of newer, self-administered injectables and oral dosages, many specialty products are and will be reimbursed through a pharmacy benefit, in contrast to a medical benefit, which covers products administered in a hospital or clinic.
The Artemetrx report, titled Specialty Drug Trend Across the Pharmacy and Medical Benefit, found that commercial health plans would do well to integrate management strategies across the pharmacy and medical benefit, the latter being “richest in savings opportunities,” from a payer perspective. Indeed, the “identification of lower cost sites of care under the medical benefit is often the most significant area of opportunity [for savings] in terms of total dollars,” according to the report.
Since a premium is commanded for drugs (and services) provided in a hospital or clinic, should pharma target the medical benefit as the reimbursement channel of choice for specialty drugs? Not necessarily, says Mason Tenaglia, managing director at the Amundsen Group. Drug companies “have a lot more control” over reimbursement when it happens “through the pharmacy channel, because [drug makers] have the opportunity to go directly to the patient and physician, as opposed to being controlled by an institutional setting and a purchasing department.”
Medicare, for example, might pay more for a cancer treatment administered at a hospital, than it would for an oral drug that offers the same health outcome, says Tenaglia. In this scenario, the cost of an oral drug, processed through a pharmacy benefit, would be shouldered to a larger extent by the patient.
With ongoing discussions around the cost of healthcare, at the state and federal level, it’s likely that public and private plans alike will continue to squeeze cost savings from the system whenever possible. Given the costs associated with specialty drugs, and the increasing number of biologic drug approvals, pharma will need to anticipate the squeeze, and figure out, on a case by case (and drug by drug) basis, which reimbursement channel provides the most favorably contoured corset.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.